Search Results - "LORD, Sarah J"

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer by Ding, Pei Ni, Lord, Sarah J, Gebski, Val, Links, Matthew, Bray, Victoria, Gralla, Richard J, Yang, James Chih-Hsin, Lee, Chee Khoon

“…Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity…”
Get more information

Accuracy and Surgical Impact of Magnetic Resonance Imaging in Breast Cancer Staging: Systematic Review and Meta-Analysis in Detection of Multifocal and Multicentric Cancer by HOUSSAMI, Nehmat, CIATTO, Stefano, MACASKILL, Petra, LORD, Sarah J, WARREN, Ruth M, DIXON, J. Michael, IRWIG, Les

“…PURPOSE We review the evidence on magnetic resonance imaging (MRI) in staging the affected breast to determine its accuracy and impact on treatment. METHODS…”
Get full text

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer by Tjokrowidjaja, Angelina, Lord, Sarah J., John, Thomas, Lewis, Craig R., Kok, Peey‐Sei, Marschner, Ian C., Lee, Chee K.

“…BACKGROUND The survival outcomes of patients with advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are variable…”
Get full text

When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? by LORD, Sarah J, IRWIG, Les, SIMES, R. John

“…The clinical value of using a new diagnostic test depends on whether it improves patient outcomes beyond the outcomes achieved using an old diagnostic test…”
Get full text

Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance by Cho, Doah, Cheyne, Saskia, Lord, Sarah J, Simes, John, Lee, Chee Khoon

“…ObjectivesCancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined…”
Get full text

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort by Daniels, Benjamin, Kiely, Belinda E., Tang, Monica, Houssami, Nehmat, Lord, Sarah J., Pearson, Sallie-Anne

“…We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic…”
Get full text

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis by Fisher, Oliver M, Lord, Sarah J, Falkenback, Dan, Clemons, Nicholas J, Eslick, Guy D, Lord, Reginald V

“…To clarify the prognostic role of tumour protein 53 (TP53) mutations in patients with oesophageal adenocarcinoma (OAC) as there is a need for biomarkers that…”
Get more information

Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma by Whiteman, David C, Appleyard, Mark, Bahin, Farzan F, Bobryshev, Yuri V, Bourke, Michael J, Brown, Ian, Chung, Adrian, Clouston, Andrew, Dickins, Emma, Emery, Jon, Eslick, Guy D, Gordon, Louisa G, Grimpen, Florian, Hebbard, Geoff, Holliday, Laura, Hourigan, Luke F, Kendall, Bradley J, Lee, Eric YT, Levert-Mignon, Angelique, Lord, Reginald V, Lord, Sarah J, Maule, Derek, Moss, Alan, Norton, Ian, Olver, Ian, Pavey, Darren, Raftopoulos, Spiro, Rajendra, Shan, Schoeman, Mark, Singh, Rajvinder, Sitas, Freddy, Smithers, B Mark, Taylor, Andrew C, Thomas, Melissa L, Thomson, Iain, To, Henry, von Dincklage, Jutta, Vuletich, Christine, Watson, David I, Yusoff, Ian F

“…Barrett's esophagus (BE), a common condition, is the only known precursor to esophageal adenocarcinoma (EAC). There is uncertainty about the best way to manage…”
Get full text

How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country by Velentzis, Louiza S., Caruana, Michael, Simms, Kate T., Lew, Jie‐Bin, Shi, Ju‐Fang, Saville, Marion, Smith, Megan A., Lord, Sarah J., Tan, Jeffrey, Bateson, Deborah, Quinn, Michael, Canfell, Karen

“…Primary HPV screening enables earlier diagnosis of cervical lesions compared to cytology, however, its effect on the risk of treatment and adverse obstetric…”
Get full text

Protocol for Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomised quality improvement initiative by Pickering, John W, Devlin, Gerard, Body, Richard, Aldous, Sally, Jaffe, Allan S, Apple, Fred S, Mills, Nicholas, Troughton, Richard W, Kavsak, Peter, Peacock, W Frank, Cullen, Louise, Lord, Sarah J, Müller, Christian, Joyce, Laura, Frampton, Chris, Lacey, Cameron James, Richards, Arthur M, Pitama, Suzanne, Than, Martin

“…IntroductionClinical assessment in emergency departments (EDs) for possible acute myocardial infarction (AMI) requires at least one cardiac troponin (cTn)…”
Get full text

Prediction of pre-eclampsia in nulliparous women using routinely collected maternal characteristics: a model development and validation study by Al-Rubaie, Ziad T A, Hudson, H Malcolm, Jenkins, Gregory, Mahmoud, Imad, Ray, Joel G, Askie, Lisa M, Lord, Sarah J

“…Guidelines recommend identifying in early pregnancy women at elevated risk of pre-eclampsia. The aim of this study was to develop and validate a pre-eclampsia…”
Get full text

Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation framework by Cho, Doah, Lord, Sarah J, Ward, Robyn, IJzerman, Maarten, Mitchell, Andrew, Thomas, David M, Cheyne, Saskia, Martin, Andrew, Morton, Rachael L, Simes, John, Lee, Chee Khoon

“…Advances in targeted therapy development and tumor sequencing technology are reclassifying cancers into smaller biomarker-defined diseases. Randomized…”
Get full text

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016) by Daniels, Benjamin, Girosi, Federico, Tervonen, Hanna, Kiely, Belinda E, Lord, Sarah J, Houssami, Nehmat, Pearson, Sallie-Anne

“…Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to…”
Get full text

Nerve root sedimentation sign: evaluation of a new radiological sign in lumbar spinal stenosis by Barz, Thomas, Melloh, Markus, Staub, Lukas P, Lord, Sarah J, Lange, Jörn, Röder, Christoph P, Theis, Jean-Claude, Merk, Harry R

“…Retrospective case-referent study. To assess whether the new sedimentation sign discriminates between nonspecific low back pain (LBP) and symptomatic lumbar…”
Get full text

Granzyme B: a natural born killer by Lord, Sarah J., Rajotte, Ray V., Korbutt, Gregory S., Bleackley, R. Chris

“…A main pathway used by cytotoxic T lymphocytes (CTLs) and natural killer cells to eliminate pathogenic cells is via exocytosis of granule components in the…”
Get full text

The AEDUCATE Collaboration. Comprehensive antenatal education birth preparation programmes to reduce the rates of caesarean section in nulliparous women. Protocol for an individual participant data prospective meta-analysis by Levett, Kate M, Lord, Sarah J, Dahlen, Hannah G, Smith, Caroline A, Girosi, Federico, Downe, Soo, Finlayson, Kenneth William, Fleet, Julie, Steen, Mary, Davey, Mary-Ann, Newnham, Elizabeth, Werner, Anette, Arnott, Leslie, Sutcliffe, Kerry, Seidler, Anna Lene, Hunter, Kylie Elizabeth, Askie, Lisa

“…Rates of medical interventions in normal labour and birth are increasing. This prospective meta-analysis (PMA) proposes to assess whether the addition of a…”
Get full text

Breast cancer screening: emerging role of new imaging techniques as adjuncts to mammography by Houssami, Nehmat, Lord, Sarah J, Ciatto, Stefano

“…Early detection of breast cancer has been shown to reduce breast cancer deaths in randomised controlled trials (RCTs) of mammography in women aged 50–69 years,…”
Get full text

Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis by Lord, Sarah J, Marinovich, M Luke, Patterson, Jillian A, Wilcken, Nicholas, Kiely, Belinda E, Gebski, Val, Crossing, Sally, Roder, David M, Gattellari, Melina, Houssami, Nehmat

“…Objectives: To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non‐metastatic breast cancer. Design,…”
Get full text

Breast Cancer Risk and Hormone Receptor Status in Older Women by Parity, Age of First Birth, and Breastfeeding: A Case-Control Study by LORD, Sarah J, BEMSTEIN, Leslie, BURKMAN, Ronald T, DEAPEN, Dennis, SPIRTAS, Robert, URSIN, Giske, JOHNSON, Karen A, MALONE, Kathleen E, MCDONALD, Jill A, MARCHBANKS, Polly A, SIMON, Michael S, STROM, Brian L, PRESS, Michael F, FOLGER, Suzanne G

“…Background: Early age at first birth and multiparity reduce the risk of estrogen receptor-progesterone receptor (ERPR)–positive breast cancer, whereas…”
Get full text

Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis by Martin, Andrew J, Lord, Sarah J, Verry, Hannah E, Stockler, Martin R, Emery, Jon D

“…Objectives: To apply the most recent evidence from randomised trials of prostate‐specific antigen (PSA) screening and explore the potential value of risk…”
Get full text